Plos One - There are robust data supporting the contribution of oxaliplatin (L-OHP) regarding clinical outcomes for colorectal cancer in an adjuvant setting in European and US trials; however, there is no Japanese clinical evidence although L-OHP has been approved since 2009. For this reason, a group of Japanese scientists decided to examine the transition of adjuvant chemotherapy for stage III colorectal cancer their own institute.

 

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer

 

Authors: Hiroki Osumi, Eiji Shinozaki , Mitsukuni Suenaga, Takeru Wakatsuki, Izuma Nakayama, Tomohiro Matsushima, Mariko Ogura, Takashi Ichimura, Daisuke Takahari, Keisho Chin, Toshiya Nagasaki, Tsuyoshi Konishi, Takashi Akiyoshi, Kensei Yamaguchi

Plos One - https://doi.org/10.1371/journal.pone.0176745 - May 31, 2017